How do you differentiate the pharmacokinetics of the LNP carrier from the saRNA payload?

We employ a multi-analyte bioanalytical strategy. The LNP carrier is typically quantified by measuring a specific lipid component via LC-MS/MS. The saRNA payload is quantified using sequence-specific RT-qPCR. This dual approach allows us to independently model the distribution and clearance of the delivery vehicle and the RNA construct, providing a complete picture of the system’s behavior.

What bioanalytical methods are optimal for quantifying saRNA and its expressed protein product in tissue?

For saRNA in tissue homogenates, validated RT-qPCR assays offer the necessary sensitivity and specificity. For the resulting expressed protein, the choice of assay depends on the protein’s nature. Ligand binding assays (e.g., ELISA, MSD) are commonly used for secreted proteins, while LC-MS/MS or Western Blot may be required for intracellular or complex proteins. We develop and validate the appropriate assays under GxP conditions for your specific program.

How does the self-amplifying nature of saRNA impact PK study design compared to conventional mRNA?

The amplification mechanism introduces a temporal disconnect between initial drug distribution and maximal protein expression. Standard PK study designs must be modified to include extended time points to accurately capture the onset, peak, and duration of protein expression (pharmacodynamics). This allows for a comprehensive characterization of the exposure-response relationship, which is distinct from the rapid onset and decay seen with non-amplifying mRNA.

What are the key considerations for assessing non-target tissue biodistribution?

A key consideration is quantifying both the LNP and the saRNA in a broad panel of tissues over time. This helps identify potential accumulation sites for the delivery vehicle and sites of unintended RNA expression. We correlate these findings with histology data to evaluate any potential local toxicity, providing a robust dataset for the regulatory submission.

The pharmacokinetic profile of a self-amplifying RNA (saRNA) therapeutic is a composite of two distinct processes: the distribution and clearance of the lipid nanoparticle (LNP) carrier and the subsequent amplification and translation of its RNA payload. A robust preclinical program must deconstruct these interconnected events to establish a clear exposure-response relationship. This requires specialized bioanalytical assays and study designs that account for the delayed and sustained protein expression characteristic of saRNA, providing the data needed to support a successful Investigational New Drug (IND) application.

IND-Enabling Studies for RNA Therapeutics

The ultimate goal of a preclinical program is to generate a data package that supports clinical development. By integrating quantitative bioanalysis with functional readouts, we provide a comprehensive profile of your saRNA candidate. This approach of Accelerated PK Profiling for Rapid Dose Optimization helps refine candidate selection and establish a safe starting dose for first-in-human studies.

Operating from our >100,000 sq ft facility, we execute these complex studies with the scientific rigor required for regulatory success. Franklin Biolabs, a brand launched in 2024, inherits a legacy of a 100% IND success rate for programs initiated since 2019, with a typical program timeline of 18-24 months. All studies are conducted in compliance with our Animal Welfare program, which is registered with the USDA and upholds the principles of the 3Rs.